The first participants have been dosed in SAFYR, a Phase I clinical trial to test the safety and efficacy of two prophylactic vaccines developed with A...
EG110A to start Phase 1b/2a clinical study in Neurogenic Detrusor Overactivity (NDO) patients NDO is a severe bladder condition affecting millions of ...
Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in Radiopharm Offer price for the shares of A$0.05 represents a 47...
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, unveiled a new clinical research laboratory build...
Labcorp a global leader of innovative and comprehensive laboratory services, announced the launch of Labcorp Global Trial Connect, a suite of...
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, is embracing the theme of the 60th annual Drug ...
Positive results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE®(acalabrutinib) in combination with bendamustine and rituximab de...
LIXTE Biotechnology Holdings, Inc. a clinical stage pharmaceutical company, today announced a collaboration with Roche and the Netherlands Cancer I...
Pfizer announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational min...
Repare Therapeutics , a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camons...
NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, a...
Eisai Co., and Biogen announced that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Supplemental Biologics License Applicat...
HUTCHMED (China) announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in Ch...
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy ...
© 2025 Biopharma Boardroom. All Rights Reserved.
